Adherium Ltd (ASX: ADR) Share Price and News

Mr Panaccio is also the Non-executive Chairman of Unison Housing Limited, Magellan Stem Cells Pty Ltd and commenced as a Director of Mecwacare Limited in December 2024. Mr Panaccio was the Chief Executive Officer and Executive Director of Melbourne Pathology for ten years to 2001, the Chief Executive Officer of Monash IVF until 2009 and the Executive Chairman of Health Networks Australia until 2017. He is member of Risk Committee.

Mr McHarrie is a company director and adviser in the health and life sciences sectors with over 30 years' experience. He was formerly with Telethon Kids Institute in Perth, Western Australia, for 15 years, where his roles included Chief Financial Officer, Director of Operations and Director of Strategic Projects. Prior to joining Telethon Kids, Mr McHarrie was a Senior Manager at Deloitte in London before moving to Rothschild Asset Management as Assistant Director of the Bioscience Unit, a life sciences private equity group investing in early-stage biotechnology and healthcare companies. Outside his role at Adherium, he is currently an advisor to BioScience Managers (manager of a shareholder in Adherium). Mr McHarrie was previously a director at AusCann Group Holdings Ltd and Pharmamark Nutrition Pty Ltd. As noted, as an advisor to BioScience Managers, Mr McHarrie has an association with a shareholder of the Company. The board of directors is of the opinion that this does not compromise Mr McHarrie's independence as to the best of the board's knowledge he is not involved in decision making by BioScience Managers and the value of the advisory services provided is not material. He is chair of Risk Committee.

Mr Cook is an investor in the Australian life science sector. He was formerly head of the life science private equity team at Rothschild Asset Management in the UK. At Rothschild, Mr Curnock Cook was responsible for the launch of the first dedicated biotechnology fund for the Australian market. Over his 40-year career, Mr Curnock Cook is experienced in creating value in emerging biotech enterprises, through participation with management. He has served on over 40 boards in roles, including chair of private and public biotechnology companies listed on NASDAQ, AMEX, LSE, TSX and ASX. He is currently Managing Director of BioScience Managers (manager of a major shareholder in Adherium), and sits on the board of Avita Medical, Rex Bionics Pty Ltd, Humanetix Ltd, Marine Department Ltd, Cambridge Respiratory Innovations Ltd, and Sea Dragon Ltd. He has held no other Australian public company directorships in the last three years. As noted, Mr Curnock Cook has an association with shareholders through his capacity as Managing Director of BioScience Managers Pty Ltd.

Mr Baran has over 35 years of experience in the medical device industry and serves as Executive Chair of the Trudell Medical Limited Board of Directors as well as being a shareholder. In addition to his role at Trudell, Mr Baran is an investor in and Director of several medical device and e-health/ connected care companies including Sensory Technologies, Mozzaz Corporation, and Sky Medical Technology Inc. Mr Baran has been responsible for the marketing of new drug delivery technologies to medical opinion leaders and pharmaceutical companies. This has included collaboration with business and clinical partners in the design and co-ordination of clinical studies. He has also been granted several US and international patents for medical devices for drug delivery and minimally invasive surgery. Mr Baran currently serves on the Advisory Board of the Lawrence National Centre for Policy and Management.

Mr Gessner has more than 25 years experience serving in leadership roles for Pfizer, Teva, AstraZeneca and GlaxoSmithKline (GSK). He brings experience in leading digital health transformation in global respiratory health markets. In particular, he is experienced in market access, product launch strategy and leveraging the very latest applications of AI in healthcare.

-

-

-

-